BioMerieux Income from Continuous Operations 2017-2024 | BMXMF
BioMerieux annual/quarterly income from continuous operations history and growth rate from 2017 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- BioMerieux income from continuous operations for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- BioMerieux income from continuous operations for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- BioMerieux annual income from continuous operations for 2024 was $0.46B, a 31.67% increase from 2023.
- BioMerieux annual income from continuous operations for 2023 was $0.349B, a 26.91% decline from 2022.
- BioMerieux annual income from continuous operations for 2022 was $0.478B, a 32.46% decline from 2021.
| BioMerieux Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024 | $460 |
| 2023 | $349 |
| 2022 | $478 |
| 2021 | $708 |
| 2020 | $460 |
| 2019 | $302 |
| 2018 | $302 |
| 2017 | $269 |
| 2016 | $198 |
| 2015 | $0 |
| BioMerieux Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.407B | $4.307B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||